The Clinical Introduction of Genetic Testing for Alzheimer DiseaseAn Ethical Perspective
- 12 March 1997
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 277 (10) , 832-836
- https://doi.org/10.1001/jama.1997.03540340066035
Abstract
Objective. —Primary caregivers should be aware of recent progress in the genetics of Alzheimer disease (AD) and of the clinical and ethical considerations raised regarding the introduction of genetic testing for purposes of disease prediction and susceptibility (risk) analysis in asymptomatic individuals and diagnosis in patients who present clinically with dementia. This statement addresses arguments for and against clinical genetic testing. Participants. —The 20 participants were selected by the investigators (S.G.P., T.H.M., A.B.Z., and P.J.W.) to achieve balance in the areas of genetics, counseling, ethics, and public policy, and to include leadership from related consensus projects. The consensus group met twice in closed meetings and carried on extensive correspondence over 2 years (1995-1997). The project was supported by the National Human Genome Research Institute of the National Institutes of Health. Evidence. —All 4 involved chromosomes were discussed in group meetings against a background of information from several focus group sessions with AD-affected families. The focus groups comprised volunteers identified by the Cleveland Area Chapter of the Alzheimer's Disease and Related Disorders Association and represented a variety of ethnic populations. Consensus Process. —The first draft was written in April 1996 by the principal investigator (S.G.P.) after the consensus group had met twice. The draft was mailed to all consensus group members 3 times over 6 months for extensive response and redrafting by the principal investigator until all members were satisfied. Conclusions. —Except for autosomal dominant early-onset families, genetic testing in asymptomatic individuals is unwarranted. Use ofAPOEgenetic testing as a diagnostic adjunct in patients already presenting with dementia may prove useful but it remains under investigation. The premature introduction of genetic testing and possible adverse consequences are to be avoided.Keywords
This publication has 13 references indexed in Scilit:
- APOE Genotype and Alzheimer´s DiseaseDementia and Geriatric Cognitive Disorders, 2000
- Evaluation of Suspected DementiaNew England Journal of Medicine, 1996
- Evaluation of DementiaNew England Journal of Medicine, 1996
- Is There a Role for Estrogen Replacement Therapy in the Prevention and Treatment of Dementia?Journal of the American Geriatrics Society, 1996
- Presenilins and Alzheimer diseaseNature Genetics, 1995
- Why do DNA testing? Practical and ethical implications of new neurogenetic testsAnnals of Neurology, 1995
- Apolipoprotein E Affects the Rate of Alzheimer Disease Expression: β-Amyloid Burden Is a Secondary Consequence Dependent on APOE Genotype and Duration of DiseaseJournal of Neuropathology and Experimental Neurology, 1994
- Promotional metaphors and their popular appealPublic Understanding of Science, 1994
- Presymptomatic testing for huntington diseases: Recommendations for counselingJournal of Genetic Counseling, 1992
- Clinical Genetics and Genetic Counseling in Alzheimer DiseaseAnnals of Internal Medicine, 1991